Bettering Me

ADHD Medication for Perimenopausal Brain Fog: What the Early Trials Show

Woman in a white shirt rests her chin on her hand and holds her glasses, looking tired and unfocused at a laptop on a desk
Photo by Kaboompics.com on Pexels

Written by

–

Drafted with AI assistance and reviewed by Kurt Greiner. How we use AI.

Brain fog is one of the most common complaints in perimenopause, and there is no approved drug for it. This week Prevention reported that ADHD medications may help, based on a review presented at the Menopause Society annual meeting. The headline is bigger than the evidence. Here is what the underlying trials actually tested, and what they leave open.

What was reported

According to Prevention, Pallavi Khanna, M.D., a professor of obstetrics and gynecology at the University of Tennessee, and her coauthors presented a review of ADHD medications for what they call perimenopausal executive dysfunction. The review found just three small trials, all from the same research group. Dr. Khanna described the evidence as “promising but early.” Two drugs, lisdexamfetamine (Vyvanse) and atomoxetine (Strattera), helped women feel they were functioning better, although their scores on objective tests did not improve.

That was a conference presentation, and we could not find a published paper for the review itself. So we went to the published trials from the research group behind this idea, which are the closest thing to primary evidence available.

What the trials found

Executive function covers planning, focusing, holding information in mind and switching between tasks. In all three trials, the women were healthy, in perimenopause or early postmenopause, reported new executive-function problems in midlife, and had no history of ADHD. That matters: these are not trials in women who already have ADHD.

The first was a small placebo-controlled crossover trial of atomoxetine in 16 women, at 80 mg a day for 6 weeks, with a 4-week break between treatments. Twelve completed both arms. On a self-rating questionnaire (the Brown Attention Deficit Disorder Scale), total scores improved during atomoxetine but not during placebo, and atomoxetine beat placebo on the working memory cluster. The attention and concentration cluster showed only a trend. Atomoxetine did not differ from placebo on neuropsychological tests, behavioral assessments or cardiac vital signs.[1]

A later crossover trial gave lisdexamfetamine, 40 to 60 mg a day for 4 weeks, to 32 women. Self-rated scores improved significantly over placebo, in total and on four of five subscales. One objective measure, delayed recall of a paragraph, also improved, but the other cognitive measures did not. Systolic blood pressure and heart rate rose on the drug, though they stayed within the normal range on average.[2]

A third study, in 14 women, used brain imaging to ask how lisdexamfetamine might work. Treatment was associated with lower symptom severity, more activity in the insula and the dorsolateral prefrontal cortex during a memory task, and a lower level of glutamate-related chemistry in that prefrontal region. It suggests the drug does something measurable in brain areas tied to executive function, but it does not show a clinical benefit on its own.[3]

The Prevention report says objective performance did not improve. The 2015 lisdexamfetamine paper did find one objective gain, so the picture is a little less uniform than the summary suggests. The broad pattern still holds: the clearest benefit was in how women rated their own functioning.

Why the idea is plausible

Dr. Khanna explained to Prevention that the prefrontal cortex works best when dopamine and norepinephrine are at the right level, and that estradiol helps keep dopamine signaling in that range. When estradiol drops in perimenopause, the pattern can resemble ADHD: trouble focusing, holding information and staying organized. ADHD medicines raise dopamine and norepinephrine, so they are a logical candidate. That is a hypothesis from an expert, not something these trials proved. The overlap with ADHD symptoms is also why we covered the link between ADHD and menopause in our post on what the research shows and what to ask a clinician.

Context helps here. A 2023 review found that cognitive problems are common in perimenopause and that many perimenopausal treatment trials are small and underpowered.[4]

What this does not show

  • The samples were small (16, 32 and 14 women), and, according to the review coverage, all from one research group. Independent replication is what would make this more than a lead.
  • The women had no history of ADHD, and the main outcome was self-rated. Self-report captures real-life struggle that lab tests can miss, but it is also more open to expectation effects than a lab test, even in a blinded trial.
  • The treatment periods were 4 to 6 weeks. Nothing here speaks to long-term benefit or long-term safety.
  • Lisdexamfetamine raised blood pressure and heart rate in the trial. Averages stayed normal, but averages can hide individuals who do not.
  • Neither drug is approved for perimenopausal brain fog. Dr. Khanna told Prevention there is no FDA-approved treatment for it.
  • We did not review the conference materials or check who funded the trials.

What to do with this

Dr. Khanna told Prevention she would not use these drugs for every case of brain fog. Her order of steps, as reported: rule out and treat other causes such as sleep problems, consider hormone therapy if other perimenopause symptoms call for it, and refer to psychiatry for a full evaluation if cognitive complaints persist or an ADHD screen is positive.

A few things you can do before that conversation:

  • Write down what changed and when: focus, memory, sleep, mood, cycle changes. A pattern is more useful to a clinician than a general complaint.
  • Look at sleep first. Poor sleep alone can produce attention and memory problems that look like brain fog.
  • Ask for the usual suspects to be checked together: thyroid problems, depression, anxiety, sleep disorders and the medicines you already take.
  • Do not borrow or start an ADHD medication on your own. These are prescription drugs that can raise blood pressure and heart rate, and the decision depends on your full history.

If the fog is the main thing, our post on whether menopause brain fog is permanent and the one on perimenopause beyond hot flashes cover the wider picture.

References

↑︎ Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE. Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. Menopause. 2011;18(5):542-548. Population: 16 healthy perimenopausal and postmenopausal women with midlife-onset subjective memory and attention difficulties and no history of ADHD; double-blind, placebo-controlled crossover, atomoxetine 80 mg/day. DOI: https://doi.org/10.1097/gme.0b013e3181fcafd6. Finding as used: total BADDS scores decreased significantly from baseline during atomoxetine but not placebo; atomoxetine was superior to placebo on the BADDS working memory cluster, with a trend on the attention/concentration cluster; atomoxetine did not differ from placebo on neuropsychological tests, behavioral assessments or cardiac vital signs.

↑︎ Epperson CN, Shanmugan S, Kim DR, Mathews S, Czarkowski KA, Bradley J, Appleby DH, Iannelli C, Sammel MD, Brown TE. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine. Psychopharmacology. 2015;232(16):3091-3100. Population: 32 healthy perimenopausal and early postmenopausal women with midlife-onset executive function difficulties; lifetime ADHD exclusionary; double-blind, placebo-controlled crossover, lisdexamfetamine 40-60 mg/day for 4 weeks. DOI: https://doi.org/10.1007/s00213-015-3953-7. Finding as used: significant effect of lisdexamfetamine over placebo on total BADDS scores (p = 0.0001) and four of five subscales (all p < 0.004); significant improvement in delayed paragraph recall (p = 0.018) with no significant effect on other cognitive measures; systolic blood pressure (p = 0.017) and heart rate (p = 0.006) increased but remained, on average, within the normal range.

↑︎ Shanmugan S, Loughead J, Nanga RPR, Elliott M, Hariharan H, Appleby D, Kim D, Ruparel K, Reddy R, Brown TE, Epperson CN. Lisdexamfetamine effects on executive activation and neurochemistry in menopausal women with executive function difficulties. Neuropsychopharmacology. 2017;42(2):437-445. Population: 14 women, 7T neuroimaging, double-blind, placebo-controlled crossover. DOI: https://doi.org/10.1038/npp.2016.162. Finding as used: lisdexamfetamine was associated with decreased symptom severity, increased activation in the insula and dorsolateral prefrontal cortex, and decreased dorsolateral prefrontal glutamate+glutamine.

↑︎ Metcalf CA, Duffy KA, Page CE, Novick AM. Cognitive problems in perimenopause: a review of recent evidence. Current Psychiatry Reports. 2023. Population: narrative review of recent research. DOI: https://doi.org/10.1007/s11920-023-01447-3. Finding as used: cognitive problems are common during perimenopause, and perimenopausal treatment trials are frequently underpowered.

Kurt Greiner
Kurt Greiner

Kurt is a digital strategist and IT professional blending emerging technology with practical application, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website provides wellness information for educational purposes only. It is not medical advice. Consult a healthcare professional before making any health-related decisions or changes.

Bettering Me Wellness 40+ logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.